Scarica l'app Stockscreener
87.46
1.48%
-1.31
Dopo l'orario di chiusura:
87.95
0.49
+0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$88.77
Aprire:
$87.89
Volume 24 ore:
681.26K
Relative Volume:
0.57
Capitalizzazione di mercato:
$21.98B
Reddito:
$3.32B
Utile/perdita netta:
$-1.26B
Rapporto P/E:
-16.72
EPS:
-5.2311
Flusso di cassa netto:
$289.80M
1 W Prestazione:
-2.07%
1M Prestazione:
-19.61%
6M Prestazione:
-10.83%
1 anno Prestazione:
-8.80%
Intervallo 1D:
$87.18
$89.33
Intervallo di 1 settimana:
$86.33
$90.94
Portata 52W:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
87.46 | 22.31B | 3.32B | -1.26B | 289.80M | -5.2311 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2026-01-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2025-06-05 | Reiterato | H.C. Wainwright | Buy |
| 2025-05-29 | Iniziato | Goldman | Neutral |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-01-10 | Iniziato | Truist | Buy |
| 2024-12-11 | Iniziato | Wells Fargo | Overweight |
| 2024-12-02 | Reiterato | BMO Capital Markets | Outperform |
| 2024-11-19 | Iniziato | Berenberg | Buy |
| 2024-11-19 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-11-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-09-24 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-09-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-08-02 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-05-14 | Iniziato | Evercore ISI | In-line |
| 2024-02-23 | Iniziato | BMO Capital Markets | Outperform |
| 2024-01-05 | Iniziato | Oppenheimer | Perform |
| 2023-12-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-10-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-17 | Aggiornamento | Redburn | Neutral → Buy |
| 2022-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-08-17 | Iniziato | Cowen | Market Perform |
| 2022-07-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-07-06 | Ripresa | Canaccord Genuity | Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2021-12-16 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2021-10-22 | Iniziato | Deutsche Bank | Hold |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-08-11 | Aggiornamento | Bryan Garnier | Neutral → Buy |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-06-16 | Downgrade | Redburn | Neutral → Sell |
| 2021-05-18 | Iniziato | Goldman | Neutral |
| 2021-05-11 | Downgrade | Bryan Garnier | Buy → Neutral |
| 2020-12-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-08-03 | Ripresa | Berenberg | Buy |
| 2020-07-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-30 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-05-19 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-28 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-03-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-03-09 | Iniziato | H.C. Wainwright | Neutral |
| 2020-01-24 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-01-22 | Downgrade | UBS | Buy → Neutral |
| 2019-11-05 | Iniziato | Wolfe Research | Outperform |
| 2019-11-04 | Iniziato | Berenberg | Buy |
| 2019-11-04 | Iniziato | BofA/Merrill | Buy |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-11-04 | Iniziato | JP Morgan | Overweight |
| 2019-11-04 | Iniziato | SVB Leerink | Outperform |
| 2019-11-04 | Iniziato | UBS | Buy |
Mostra tutto
Biontech Se Adr Borsa (BNTX) Ultime notizie
BioNTech stock plunges as founders leave. Should you buy the dip in BNTX here? - MSN
BioNTech Oncology Pipeline Shows Promising Survival Data in Late-Stage Lung Cancer Trials as of Marc - AD HOC NEWS
Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer - GlobeNewswire Inc.
AKT I: „ICI VARSOVIE” [c66293] - Fathom Journal
BioNTech's Oncology Pivot Accelerates Amid Leadership Transition and €17B Cash Reserve - AD HOC NEWS
Hudson Bay Capital Management LP Acquires 55,004 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Stock Forecast | Co-Founders Plan Departure - Capital.com
Groupama Asset Managment Trims Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
Long Focus Capital Management LLC Has $39.22 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BioNTech a Takeover Target? What's Happening at CHAR Technologies and Steyr Motors? - news.financial
symbol__ Stock Quote Price and Forecast - CNN
125,000 Shares in BioNTech SE Sponsored ADR $BNTX Purchased by Ghisallo Capital Management LLC - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Acquired by Dodge & Cox - MarketBeat
BioNTech SE Stock (ISIN: US09075V1026) Faces Pressure After Leadership Exodus and Earnings Miss - AD HOC NEWS
BNP Paribas Financial Markets Lowers Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech (NASDAQ:BNTX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Serve Robotics Posts Upbeat Q4 Results, Joins Auna, Acacia Research And Other Big Stocks Moving Higher On Wednesday - Benzinga
BMO cuts BioNTech stock price target on CEO departure plans - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Sold by Capital International Inc. CA - MarketBeat
BioNTech tumbles over 19% on fourth quarter earnings miss - Investing.com
Oppenheimer maintains BioNTech stock rating amid leadership exit - Investing.com
BioNTech stock price target lowered to $167 by Clear Street - Investing.com
BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here? - inkl
Truist reiterates Buy on BioNTech stock after revenue guidance - Investing.com
BofA cuts BioNTech stock price target on leadership transition - Investing.com South Africa
Micron and BioNTech among market cap stock movers on Tuesday By Investing.com - Investing.com India
Micron and BioNTech among market cap stock movers on Tuesday - Investing.com
BioNTech (NASDAQ:BNTX) Hits New 1-Year LowHere's What Happened - MarketBeat
BioNTech Q4 Earnings Call Highlights - Yahoo Finance
BioNTech co-founding couple Sahin and Tuereci leaving to create new company - The Globe and Mail
FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
BioNTech founders to establish new mRNA company, step down by year-end - Investing.com
BioNTech earnings loom with revenue dive, pipeline progress in focus - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Acquired by Victory Capital Management Inc. - MarketBeat
BioNTech's Upcoming Financial Report Draws Investor Scrutiny Amid Strategic Pivot () - aktiencheck.de
Is BioNTech SE (BNTX) A Good Stock To Buy Now? - Finviz
BioNTech Expands Infectious Disease Pipeline With New Mpox mRNA Vaccine Trial in Africa - TipRanks
Sobre Bruno Hansmann - eToro
Primecap Management Co. CA Sells 130,700 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
BioNTech Escalates mRNA Legal Battle with Moderna Over Next-Gen Vaccine () - aktiencheck.de
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BioNTech’s New HIV Antibody Trial Adds Depth to BNTX’s Long-Term Pipeline Story - TipRanks
Biontech Se Adr Azioni (BNTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.06%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):